BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 26594835)

  • 21. A prospective study investigating the impact of multiparametric MRI in biopsy-naïve patients with clinically suspected prostate cancer: The PROKOMB study.
    Baur ADJ; Henkel T; Johannsen M; Speck T; Weißbach L; Hamm B; König F
    Contemp Clin Trials; 2017 May; 56():46-51. PubMed ID: 28279782
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy.
    Mannaerts CK; Gayet M; Verbeek JF; Engelbrecht MRW; Savci-Heijink CD; Jager GJ; Gielens MPM; van der Linden H; Beerlage HP; de Reijke TM; Wijkstra H; Roobol MJ
    Eur Urol Oncol; 2018 Jun; 1(2):109-117. PubMed ID: 31100233
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.
    Radtke JP; Wiesenfarth M; Kesch C; Freitag MT; Alt CD; Celik K; Distler F; Roth W; Wieczorek K; Stock C; Duensing S; Roethke MC; Teber D; Schlemmer HP; Hohenfellner M; Bonekamp D; Hadaschik BA
    Eur Urol; 2017 Dec; 72(6):888-896. PubMed ID: 28400169
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Value of 3-Tesla multiparametric magnetic resonance imaging and targeted biopsy for improved risk stratification in patients considered for active surveillance.
    Pessoa RR; Viana PC; Mattedi RL; Guglielmetti GB; Cordeiro MD; Coelho RF; Nahas WC; Srougi M
    BJU Int; 2017 Apr; 119(4):535-542. PubMed ID: 27500389
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Confirmatory biopsy of men under active surveillance: extended versus saturation versus multiparametric magnetic resonance imaging/transrectal ultrasound fusion prostate biopsy.
    Pepe P; Cimino S; Garufi A; Priolo G; Russo GI; Giardina R; Reale G; Pennisi M; Morgia G
    Scand J Urol; 2017 Aug; 51(4):260-263. PubMed ID: 28513296
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of Multiparametric MRI in 800 Men Submitted to Repeat Prostate Biopsy: Results of a Public Health Model.
    Pepe P; Pepe G; Pepe L; Garufi A; Priolo GD; Pennisi M
    Anticancer Res; 2018 Apr; 38(4):2395-2398. PubMed ID: 29599367
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Validating multiparametric MRI for diagnosis and monitoring of prostate cancer in patients for active surveillance.
    Sahibzada I; Batura D; Hellawell G
    Int Urol Nephrol; 2016 Apr; 48(4):529-33. PubMed ID: 26759330
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiparametric (mp) MRI of prostate cancer.
    Kumar V; Bora GS; Kumar R; Jagannathan NR
    Prog Nucl Magn Reson Spectrosc; 2018 Apr; 105():23-40. PubMed ID: 29548365
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiparametric Magnetic-Resonance to Confirm Eligibility to an Active Surveillance Program for Low-Risk Prostate Cancer: Intermediate Time Results of a Third Referral High Volume Centre Active Surveillance Protocol.
    Luzzago S; Musi G; Catellani M; Russo A; Di Trapani E; Mistretta FA; Bianchi R; Cozzi G; Conti A; Pricolo P; Ferro M; Matei DV; Mirone V; Petralia G; de Cobelli O
    Urol Int; 2018; 101(1):56-64. PubMed ID: 29734177
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection of Individual Prostate Cancer Foci via Multiparametric Magnetic Resonance Imaging.
    Johnson DC; Raman SS; Mirak SA; Kwan L; Bajgiran AM; Hsu W; Maehara CK; Ahuja P; Faiena I; Pooli A; Salmasi A; Sisk A; Felker ER; Lu DSK; Reiter RE
    Eur Urol; 2019 May; 75(5):712-720. PubMed ID: 30509763
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiparametric Magnetic Resonance Imaging Is an Independent Predictor of Salvage Radiotherapy Outcomes After Radical Prostatectomy.
    Sharma V; Nehra A; Colicchia M; Westerman ME; Kawashima A; Froemming AT; Kwon ED; Mynderse LA; Karnes RJ
    Eur Urol; 2018 Jun; 73(6):879-887. PubMed ID: 29195777
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low-risk prostate cancer patients without visible tumor (T1c) on multiparametric MRI could qualify for active surveillance candidate even if they did not meet inclusion criteria of active surveillance protocol.
    Lee DH; Koo KC; Lee SH; Rha KH; Choi YD; Hong SJ; Chung BH
    Jpn J Clin Oncol; 2013 May; 43(5):553-8. PubMed ID: 23580758
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiparametric magnetic resonance imaging for the assessment of extracapsular invasion and other staging parameters in patients with prostate cancer candidates for radical prostatectomy.
    Lista F; Gimbernat H; Cáceres F; Rodríguez-Barbero JM; Castillo E; Angulo JC
    Actas Urol Esp; 2014 Jun; 38(5):290-7. PubMed ID: 24387827
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multiparametric Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer: A Systematic Review.
    Haider MA; Yao X; Loblaw A; Finelli A
    Clin Oncol (R Coll Radiol); 2016 Sep; 28(9):550-67. PubMed ID: 27256655
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer.
    Amin A; Blazevski A; Thompson J; Scheltema MJ; Hofman MS; Murphy D; Lawrentschuk N; Sathianathen N; Kapoor J; Woo HH; Chalasani V; Rasiah K; van Leeuwen PJ; Tang R; Cusick T; Stricker P; Emmett L
    BJU Int; 2020 Apr; 125(4):515-524. PubMed ID: 31957122
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of Gleason 6 prostate cancer in patients with clinically significant prostate cancer on multiparametric magnetic resonance imaging.
    Chaloupka M; Bischoff R; Pfitzinger P; Lellig E; Ledderose S; Buchner A; Schlenker B; Stief C; Clevert DA; Apfelbeck M
    Clin Hemorheol Microcirc; 2019; 73(1):105-111. PubMed ID: 31561351
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Multiparametric MRI for prostate cancer screening].
    Hoeks CM; Fütterer JJ; Somford DM; van Oort IM; Huisman H; Barentsz JO
    Ned Tijdschr Geneeskd; 2009; 153():B487. PubMed ID: 20003566
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In-parallel comparative evaluation between multiparametric magnetic resonance imaging, prostate cancer antigen 3 and the prostate health index in predicting pathologically confirmed significant prostate cancer in men eligible for active surveillance.
    Porpiglia F; Cantiello F; De Luca S; Manfredi M; Veltri A; Russo F; Sottile A; Damiano R
    BJU Int; 2016 Oct; 118(4):527-34. PubMed ID: 26350955
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies.
    Pokorny MR; de Rooij M; Duncan E; Schröder FH; Parkinson R; Barentsz JO; Thompson LC
    Eur Urol; 2014 Jul; 66(1):22-9. PubMed ID: 24666839
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness analysis of multiparametric MRI with increased active surveillance for low-risk prostate cancer in Australia.
    Gordon LG; James R; Tuffaha HW; Lowe A; Yaxley J
    J Magn Reson Imaging; 2017 May; 45(5):1304-1315. PubMed ID: 27726240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.